Literature DB >> 11995813

Ki-67 labeling is correlated with the time to recurrence in primary glioblastomas.

Roland Schröder1, Klaus D Feisel, Ralf-Ingo Ernestus.   

Abstract

The Ki-67 labeling index (LI) was shown in many cut-off studies to be significantly correlated to the postoperative survival probability in gliomas in univariate and multivariate analyses. However, a direct relationship of the Ki-67 LI and the growth fraction, respectively, to clinical growth parameters was not demonstrated in a single tumor type of this group until now. We compared the Ki-67 LI of 20 primary glioblastomas and their recurrent tumors with the time to reoperation for recurrence. Regression analyses showed (1) a high reproducibility of the LIs at the second versus the first operation corresponding to an inherent growth potential of a given individual tumor and (2) a strong inverse correlation of LI to time to recurrence (TR) (r = -0.92). Additionally to a lower LI (corresponding to a smaller growth fraction), a longer cycle time could be derived in slowly growing as compared to rapidly growing tumors. A direct relationship of the Ki-67 LI to a clinical time parameter (the TR) was obtained, and a predictive significance of individual LIs in glioblastomas could be defined.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11995813     DOI: 10.1023/a:1014527929948

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  36 in total

1.  Use of MIB-1 (Ki-67) immunoreactivity in differentiating grade II and grade III gliomas.

Authors:  D W Hsu; D N Louis; J T Efird; E T Hedley-Whyte
Journal:  J Neuropathol Exp Neurol       Date:  1997-08       Impact factor: 3.685

2.  Proliferating cell nuclear antigen and Ki-67 immunohistochemistry of oligodendrogliomas with special reference to prognosis.

Authors:  S Heegaard; H M Sommer; H Broholm; O Broendstrup
Journal:  Cancer       Date:  1995-11-15       Impact factor: 6.860

3.  Proliferative activity and prognosis of low-grade astrocytomas.

Authors:  D Schiffer; P Cavalla; A Chiò; P Richiardi; M T Giordana
Journal:  J Neurooncol       Date:  1997-08       Impact factor: 4.130

4.  Meningiomas: clinical implications of a high proliferative potential determined by bromodeoxyuridine labeling.

Authors:  M Shibuya; T Hoshino; S Ito; M R Wacker; M D Prados; R L Davis; C B Wilson
Journal:  Neurosurgery       Date:  1992-04       Impact factor: 4.654

5.  Image cytometric measurement of nuclear proliferation markers (MIB-1, PCNA) in astrocytomas. Prognostic significance.

Authors:  L J Kirkegaard; P B DeRose; B Yao; C Cohen
Journal:  Am J Clin Pathol       Date:  1998-01       Impact factor: 2.493

6.  Prognostic significance of Ki67, p53 and epidermal growth factor receptor immunostaining in human glioblastomas.

Authors:  C Bouvier-Labit; O Chinot; C Ochi; D Gambarelli; H Dufour; D Figarella-Branger
Journal:  Neuropathol Appl Neurobiol       Date:  1998-10       Impact factor: 8.090

7.  Regional heterogeneity in the proliferative activity of human gliomas as measured by the Ki-67 labeling index.

Authors:  S W Coons; P C Johnson
Journal:  J Neuropathol Exp Neurol       Date:  1993-11       Impact factor: 3.685

8.  MIB-1 proliferation index predicts survival among patients with grade II astrocytoma.

Authors:  P E McKeever; M S Strawderman; B Yamini; A A Mikhail; M Blaivas
Journal:  J Neuropathol Exp Neurol       Date:  1998-10       Impact factor: 3.685

9.  Bromodeoxyuridine labeling index in glioblastoma multiforme: relation to radiation response, age, and survival.

Authors:  F G Barker; M D Prados; S M Chang; R L Davis; P H Gutin; K R Lamborn; D A Larson; M W McDermott; P K Sneed; C B Wilson
Journal:  Int J Radiat Oncol Biol Phys       Date:  1996-03-01       Impact factor: 7.038

10.  Relationships between Ki-67 labelling index, amplification of the epidermal growth factor receptor gene, and prognosis in human glioblastomas.

Authors:  S H Torp; E Helseth; A Dalen; G Unsgaard
Journal:  Acta Neurochir (Wien)       Date:  1992       Impact factor: 2.216

View more
  11 in total

1.  Evaluation of Akt and RICTOR Expression Levels in Astrocytomas of All Grades.

Authors:  Arthur William Alvarenga; Luis Eduardo Machado; Bruna Roz Rodrigues; Fernanda Cristina Sulla Lupinacci; Paulo Sanemastu; Eduardo Matta; Martín Roffé; Luís Fernando Bleggi Torres; Isabela Werneck da Cunha; Vilma Regina Martins; Glaucia Noeli Maroso Hajj
Journal:  J Histochem Cytochem       Date:  2016-10-28       Impact factor: 2.479

Review 2.  Long-term survival in a patient with glioblastoma on antipsychotic therapy for schizophrenia: a case report and literature review.

Authors:  Shahdabul Faraz; Susan Pannullo; Marc Rosenblum; Andrew Smith; A Gabriella Wernicke
Journal:  Ther Adv Med Oncol       Date:  2016-08-18       Impact factor: 8.168

3.  Role of MIB1 in predicting survival in patients with glioblastomas.

Authors:  Shaye I Moskowitz; Tao Jin; Richard A Prayson
Journal:  J Neurooncol       Date:  2006-01       Impact factor: 4.130

4.  Comparison of microRNA expression levels between initial and recurrent glioblastoma specimens.

Authors:  Aysegül Ilhan-Mutlu; Adelheid Wöhrer; Anna Sophie Berghoff; Georg Widhalm; Christine Marosi; Ludwig Wagner; Matthias Preusser
Journal:  J Neurooncol       Date:  2013-02-19       Impact factor: 4.130

5.  Recurrent glioblastoma of childhood treated with bevacizumab: case report and molecular features.

Authors:  Wei Zhang; Yi Lin; Baoshi Chen; Sonya Wei Song; Tao Jiang
Journal:  Childs Nerv Syst       Date:  2009-10-13       Impact factor: 1.475

6.  Proliferative activity of microvascular cells in glioblastomas does not correlate with time to recurrence.

Authors:  Michael A Kern; Klaus D Feisel; Michael Friese; Ralf-Ingo Ernestus; Roland Schröder
Journal:  J Neurooncol       Date:  2003-05       Impact factor: 4.130

7.  Prognostic value of Mdm2, p53 and p16 in patients with astrocytomas.

Authors:  Stella M Ranuncolo; Mirta Varela; Ana Morandi; José Lastiri; Silvia Christiansen; Elisa Bal de Kier Joffé; María G Pallotta; Lydia Puricelli
Journal:  J Neurooncol       Date:  2004-06       Impact factor: 4.130

8.  Advanced interstitial chemotherapy combined with targeted treatment of malignant glioma in rats by using drug-loaded nanofibrous membranes.

Authors:  Yuan-Yun Tseng; Chen-Hsing Su; Shun-Tai Yang; Yin-Chen Huang; Wei-Hwa Lee; Yi-Chuan Wang; Shou-Cheng Liu; Shih-Jung Liu
Journal:  Oncotarget       Date:  2016-09-13

9.  Inflammatory Tumor Microenvironment in Cranial Meningiomas: Clinical Implications and Intraindividual Reproducibility.

Authors:  Johannes Wach; Tim Lampmann; Ági Güresir; Hartmut Vatter; Ulrich Herrlinger; Albert Becker; Marieta Toma; Michael Hölzel; Erdem Güresir
Journal:  Diagnostics (Basel)       Date:  2022-03-30

10.  Unique spectral markers discern recurrent Glioblastoma cells from heterogeneous parent population.

Authors:  Ekjot Kaur; Aditi Sahu; Arti R Hole; Jacinth Rajendra; Rohan Chaubal; Nilesh Gardi; Amit Dutt; Aliasgar Moiyadi; C Murali Krishna; Shilpee Dutt
Journal:  Sci Rep       Date:  2016-05-25       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.